The United States is now in the fourth wave of the opioid overdose epidemic, an ongoing public health emergency that has seen deaths continue to rise (Mattson, 2021) as well as widespread impacts on mental and physical health, housing, job stability, and community services like healthcare (Hagemeier, 2018). Medication for opioid use disorder (MOUD) is an empirically supported treatment that reduces risk of overdose (Wakeman et al., 2020) and improves mental and physical health (Amura, 2022). Methadone, a full opioid agonist, and buprenorphine, a partial opioid agonist, are the most common forms of MOUD (Wakeman et al., 2020). However, methadone can only be dispensed by specially licensed Opioid Treatment Programs (OTPs), and typically requires frequent clinic visits. Although rule alterations during the COVID-19 pandemic eliminated daily dispensing requirements, many providers still require frequent visits for methadone dispensing (Meyerson et al., 2024). In contrast, buprenorphine can be dispensed by any physician with an appropriate DEA registration, and generally is prescribed in a way that allows for fewer clinic visits – often weekly to monthly. Use of buprenorphine expands access by increasing provision of MOUD by non-specialist providers like family medicine doctors (Olfson et al., 2020), most notably in rural and underserved areas (Abraham et al., 2020). However, buprenorphine also has poorer retention than methadone (Bell et al., 2009; Degenhardt et al., 2023; Timko et al., 2016). Indeed, in a large sample of patients on Medicaid, most patients receiving buprenorphine discontinued the medication within 3 months, with around a third discontinuing in the first month of care (Samples et al., 2018).
Scientific studies aiming to improve retention in MOUD have found Contingency Management (CM) is an effective method (Bolívar et al., 2021). CM provides rewards (e.g., gift cards) when patients achieve treatment goals, such as attending visits or submitting opioid-negative urine samples. CM has been found to be effective across a number of targets, including abstinence, medication adherence, and attendance (DeFulio & Silverman, 2012; Dugosh et al., 2016; Griffith et al., 2000; Lussier et al., 2006; Prendergast et al., 2006). However, despite strong empirical support and the existence of high-quality materials for training MOUD staff in CM (Helseth et al., 2018), only 10% of front-line MOUD staff actually use CM (McGovern et al., 2004a). There have been prior attempts to bridge this implementation gap, but these have focused on specialized treatment settings. One was in the Veteran’s Affairs system, and took advantage of the VA’s integrated care model, different reimbursement structure, and on-site resources such as canteens to provide rewards (DePhilippis et al., 2018). Other implementations have been in partnership with registered OTP providers with a majority of patients receiving methadone (Becker et al., 2019a, 2021). Both the need to improve retention and the public health benefits of improving retention using CM may be greater in non-specialty settings prescribing primarily buprenorphine, yet there may also be greater challenges in these settings. Indeed, in two state-wide implementation efforts that included a variety of sites, the authors qualitatively observed that specialty or registered OTP providers appeared better able to implement CM than generalist settings (Parent et al., 2023). Despite this need, to our knowledge, there have not been intentional attempts to fit CM for less-specialized MOUD settings like family medicine.
Prior CM implementation work has highlighted barriers/concerns such as cost, staff perceptions that programs will not address the underlying problems in addiction, and implementation based on researchers, not practitioners (Carroll, 2014; Hartzler & Rabun, 2013; Kirby et al., 2006; McGovern et al., 2004b; Roll et al., 2009). Implementing CM in less specialized but more accessible primary care clinics that rely on buprenorphine may present additional challenges. One is less frequent patient visits. The CM literature shows opportunities for reward should occur frequently (at least weekly if not more) for CM to be effective (Pfund et al., 2021); however, one advantage of buprenorphine is longer times between visits, which conflicts with this need. Indeed, this was one explanation for the greater success of OTPs in the state-wide implementation described above: more intensive treatment schedules provide more opportunities for CM (Parent et al., 2023). Another challenge is constraints on total reward value. The CM literature shows that rewards must meet a certain threshold to be effective (Becker, DiClemente-Bosco, Rash, et al., 2023). Consistent with this, prior implementations of CM utilized total reward amounts over $200 (Becker, DiClemente-Bosco, Scott, et al., 2023; Becker et al., 2019b; Hartzler et al., 2014; Petry et al., 2012a, b). However, the Centers for Medicare and Medicaid Services (CMS) sets a $75 per year per patient limit on rewards/incentives to patients, with larger amounts considered illegal "kickbacks" (Clark & Davis, 2023). The Office of the Inspector General (OIG) has held that this does not prohibit carefully-run higher-value CM programs, and has issued favorable rulings to some specific higher-value CM programs (Clark & Davis, 2023). However, large generalist health care organizations that do not specialize in opioid treatment may be more comfortable staying within the “safe harbor” limit of the OIG rather than seeking a ruling. This would limit CM programs to low-value rewards (Gerra et al., 2006; Levine et al., 2015; Marcovitz et al., 2016; Noe & Keller, 2020).
Although specific barriers and facilitators may vary in a family medicine setting, we believe the same implementation techniques that have been used to adapt CM to more specialized settings can be used effectively here (Becker et al., 2019b, 2021). These include first assessing the organization's viewpoints on and capacity for CM, using user-centered design in implementation (Lyon & Koerner, 2016), developing detailed contingency plans, and continued training and partnership (Becker, DiClemente-Bosco, Rash, et al., 2023). Here we report on the first step in this process: conducting semi-structured qualitative interviews of patients and providers to inform the user-centered design of a CM program for a family medicine clinic embedded within a federally qualified healthcare center (FQHC). These results will inform development of a CM program that improves outcomes and is primed for adoption and implementation in non-specialized clinics. User-centered design has been identified as critical to the uptake and adoption of CM, but to our knowledge this is the first that the principles of user-centered design have been used to identify considerations for implementing CM in a non-specialized primary care setting. This work also extends prior examples of user-centered design of CM (Becker et al., 2019b) by including patient perspectives in addition to staff.
We first engaged in pre-design work with key decision-makers in our community partner clinic (the senior MOUD provider and program coordinator), to identify program elements that were constrained by either scientific findings or clinic needs and thus would not be open to design input. First, the initial month of treatment was the only time patients would be seen often enough (at least weekly) for effective CM per the literature, so the program would enroll patients for their first month of treatment only. This is a comparatively short time period, especially given findings that CM effectiveness improves with longer treatment times (Petry et al., 2018; Roll et al., 2013). However, it at least covered the period with the most treatment drop-out, both per national findings and the observation of local program staff. Further, recent meta-analyses show long-term benefits even after CM discontinuation (Ginley et al., 2021). Although this was speculative, it seemed possible that better adherence and improved alliance with staff in the first month could provide some lasting benefits. Second, our partner clinic has a patient-centered, harm-reduction approach, not requiring abstinence as a goal. Thus, two non-abstinence behaviors were selected as targets: weekly attendance and weekly personal goals. Personal goals were strongly desired by clinic decision-makers, consistent with their patient-centered approach. However, another important principle of CM is that target behaviors should be clear and objectively verifiable. Personal goals are more difficult to verify, and, although they have been used previously (Lewis & Petry, 2005) they are less common targets of CM. Thus, we decided to simultaneously design two parallel programs – one targeting personal goals and one targeting attendance – to increase our odds of ultimately delivering an effective intervention. Third, to address decision-maker concerns we stayed within the <$75 “safe harbor” amount for incentives suggested by the OIG. As noted above, the literature suggests that $75 per year may not be sufficient for effective CM; however, many of the studies this statement is based on used abstinence as a goal. “Easier” behaviors, such as attendance, may be influenceable using smaller rewards, as demonstrated in prior studies (Hartzler et al., 2023; Kropp et al., 2017). Thus, this constraint also confirmed our choice of non-abstinence goals. Finally, decision-makers agreed that it would be important to use the existing electronic medical record system (EMR) (i.e. Epic - Epic Systems Corporation) to track goals and rewards, rather than custom spreadsheets or other methods used in prior CM implementations (Becker, DiClemente-Bosco, Scott, et al., 2023).
With these broad guidelines established, we then conducted semi-structured interviews with clinic patients and staff to systematically collect end-user input on implementation factors and remaining key design features, with the overall goal of informing an acceptable, adoptable, and feasible CM program for this context. We used rapid matrix analysis, a cutting-edge qualitative technique, to provide fast feedback for design and implementation (Averill, 2002).